ADHERE-S (NIS Brilique)
Non-interventional Prospective Data Collection on Persistence and Adherence on Ticagrelor in ACS Adult Patients in Serbia
1 other identifier
observational
269
1 country
9
Brief Summary
noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2018
9 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 9, 2018
CompletedFirst Posted
Study publicly available on registry
February 23, 2018
CompletedStudy Start
First participant enrolled
March 5, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 13, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
August 13, 2019
CompletedAugust 7, 2020
July 1, 2020
1.4 years
February 9, 2018
August 5, 2020
Conditions
Outcome Measures
Primary Outcomes (1)
duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome
1 year (12 months)
Interventions
persistence and adherence on ticagrelor in ACS patients
Eligibility Criteria
Adult ACS patients
You may qualify if:
- ≥ 18 years of age
- diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
- Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
- read and signed the Informed Consent Form
You may not qualify if:
- Any contraindications as per approved SmPC of Brilique
- Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (9)
CHC Bezanijska Kosa
Belgrade, Serbia
CHC Zemun
Belgrade, Serbia
CHC Zvezdara
Belgrade, Serbia
Clinical Center of Serbia
Belgrade, Serbia
Institute for cardiovascular diseases, Dedinje
Belgrade, Serbia
Medical Military Academy
Belgrade, Serbia
Institute for cardiovascular diseases of Vojvodina
Kamenitz, Serbia
Clinical Center Kragujevac
Kragujevac, Serbia
Clinical Center Nis
Niš, Serbia
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 9, 2018
First Posted
February 23, 2018
Study Start
March 5, 2018
Primary Completion
August 13, 2019
Study Completion
August 13, 2019
Last Updated
August 7, 2020
Record last verified: 2020-07